OTCMKTS:AYRSF

Ayr Strategies Competitors

$21.26
0.00 (0.00 %)
(As of 12/7/2020)
Add
Compare
Today's Range
$21.26
Now: $21.26
$21.26
50-Day Range
$21.26
MA: $21.26
$21.26
52-Week Range
$3.44
Now: $21.26
$22.77
VolumeN/A
Average Volume38,816 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Ayr Strategies (OTCMKTS:AYRSF) Vs. ABAHF, ACRGF, APPB, CANB, CNTMF, and CWBHF

Should you be buying AYRSF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Ayr Strategies, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Can B (CANB), Cansortium (CNTMF), and Charlotte's Web (CWBHF).

Ayr Strategies (OTCMKTS:AYRSF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Ayr Strategies and Abacus Health Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
Abacus Health ProductsN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ayr Strategies and Abacus Health Products, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
Abacus Health Products0000N/A

Ayr Strategies currently has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Given Ayr Strategies' higher probable upside, analysts clearly believe Ayr Strategies is more favorable than Abacus Health Products.

Earnings and Valuation

This table compares Ayr Strategies and Abacus Health Products' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
Abacus Health ProductsN/AN/AN/AN/AN/A

Summary

Ayr Strategies beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Profitability

This table compares Ayr Strategies and Acreage's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
AcreageN/AN/AN/A

Earnings & Valuation

This table compares Ayr Strategies and Acreage's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
AcreageN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Ayr Strategies and Acreage, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
Acreage01202.67

Ayr Strategies currently has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Acreage has a consensus price target of $8.4333, suggesting a potential upside of 204.45%. Given Acreage's higher probable upside, analysts plainly believe Acreage is more favorable than Ayr Strategies.

Summary

Ayr Strategies beats Acreage on 2 of the 3 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Profitability

This table compares Ayr Strategies and Applied Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
Applied BiosciencesN/AN/AN/A

Earnings & Valuation

This table compares Ayr Strategies and Applied Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
Applied BiosciencesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Ayr Strategies and Applied Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
Applied Biosciences0000N/A

Ayr Strategies currently has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Given Ayr Strategies' higher probable upside, equities research analysts plainly believe Ayr Strategies is more favorable than Applied Biosciences.

Summary

Ayr Strategies beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Profitability

This table compares Ayr Strategies and Can B's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
Can BN/AN/AN/A

Earnings & Valuation

This table compares Ayr Strategies and Can B's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
Can BN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Ayr Strategies and Can B, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
Can B0000N/A

Ayr Strategies currently has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Given Ayr Strategies' higher probable upside, equities research analysts plainly believe Ayr Strategies is more favorable than Can B.

Summary

Ayr Strategies beats Can B on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Ayr Strategies and Cansortium's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayr StrategiesN/AN/AN/AN/AN/A
CansortiumN/AN/AN/AN/AN/A

Profitability

This table compares Ayr Strategies and Cansortium's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayr StrategiesN/AN/AN/A
CansortiumN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Ayr Strategies and Cansortium, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayr Strategies01602.86
Cansortium00103.00

Ayr Strategies currently has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Cansortium has a consensus price target of $1.20, suggesting a potential upside of 35.90%. Given Ayr Strategies' higher probable upside, equities research analysts plainly believe Ayr Strategies is more favorable than Cansortium.

Summary

Ayr Strategies beats Cansortium on 2 of the 3 factors compared between the two stocks.

Charlotte's Web (OTCMKTS:CWBHF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Charlotte's Web and Ayr Strategies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charlotte's Web01302.75
Ayr Strategies01602.86

Charlotte's Web presently has a consensus target price of $7.25, suggesting a potential upside of 73.44%. Ayr Strategies has a consensus target price of $34.8571, suggesting a potential upside of 63.96%. Given Charlotte's Web's higher possible upside, analysts plainly believe Charlotte's Web is more favorable than Ayr Strategies.

Earnings and Valuation

This table compares Charlotte's Web and Ayr Strategies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charlotte's WebN/AN/AN/AN/AN/A
Ayr StrategiesN/AN/AN/AN/AN/A

Profitability

This table compares Charlotte's Web and Ayr Strategies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charlotte's WebN/AN/AN/A
Ayr StrategiesN/AN/AN/A

Summary

Ayr Strategies beats Charlotte's Web on 2 of the 3 factors compared between the two stocks.


Ayr Strategies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84flat$0.00N/A0.00Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77flat$0.00N/A0.00
Applied Biosciences logo
APPB
Applied Biosciences
0.5$0.40flat$0.00N/A0.00Increase in Short Interest
Gap Up
Can B logo
CANB
Can B
0.4$0.52flat$0.00N/A0.00Gap Down
Cansortium logo
CNTMF
Cansortium
1.1$0.88flat$0.00N/A0.00Decrease in Short Interest
Gap Up
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$4.18flat$0.00N/A0.00News Coverage
Gap Up
Choom logo
CHOOF
Choom
0.5$0.09flat$0.00N/A0.00Decrease in Short Interest
Gap Down
CPHRF
Cipher Pharmaceuticals
1.2$1.06flat$0.00N/A0.00Decrease in Short Interest
Gap Down
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.24flat$0.00N/A0.00Gap Up
Cosmos logo
COSM
Cosmos
0.5$5.75flat$0.00N/A0.00High Trading Volume
Increase in Short Interest
Cresco Labs logo
CRLBF
Cresco Labs
1.5$12.12flat$0.00N/A0.00News Coverage
Curaleaf logo
CURLF
Curaleaf
1.6$14.36flat$0.00N/A0.00Gap Up
HMDEF
DionyMed Brands
0.5N/AN/A$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00flat$0.00N/A0.00Decrease in Short Interest
Gap Down
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.15flat$0.00N/A0.00Increase in Short Interest
Gap Down
EVIO logo
EVIO
EVIO
0.6$0.00flat$0.00N/A0.00Increase in Short Interest
Gap Up
Flower One logo
FLOOF
Flower One
0.4$0.26flat$0.00N/A0.00Decrease in Short Interest
News Coverage
Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05flat$0.00N/A0.00Decrease in Short Interest
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01flat$0.00N/A0.00
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$29.49flat$0.00N/A0.00
GTEC logo
GGTTF
GTEC
0.6$0.62flat$0.00N/A0.00Increase in Short Interest
Gap Down
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$2.80flat$0.00N/A0.00Gap Up
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01flat$0.00N/A0.00Decrease in Short Interest
Hexo logo
HYYDF
Hexo
0.6N/AN/A$0.00N/A0.00
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$59.68flat$0.00N/A0.00News Coverage
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.22flat$0.00N/A0.00Gap Down
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.32flat$0.00N/A0.00Decrease in Short Interest
KNHBF
ICC International Cannabis
0.6N/AN/A$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04flat$0.00N/A0.00Decrease in Short Interest
Gap Up
Isodiol International logo
ISOLF
Isodiol International
0.4$0.05flat$0.00N/A0.00Gap Up
Khiron Life Sciences logo
KHRNF
Khiron Life Sciences
1.4$0.43flat$0.00N/A0.00Decrease in Short Interest
Gap Up
KHTRF
Knight Therapeutics
1.2$4.21flat$0.00N/A0.00
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01flat$0.00N/A0.00Increase in Short Interest
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.05flat$0.00N/A0.00
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.38flat$0.00N/A0.00Increase in Short Interest
Gap Up
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.32flat$0.00N/A0.00Increase in Short Interest
Gap Up
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$35.33flat$0.00N/A0.00Increase in Short Interest
MJardin Group logo
MJARF
MJardin Group
1.1$0.07flat$0.00N/A0.00Increase in Short Interest
Gap Up
MYHI
Mountain High Acquisitions
0.5$0.02flat$0.00N/A0.00Decrease in Short Interest
Gap Up
PHCEF
Pharmacielo
0.7$1.23flat$0.00N/A0.00News Coverage
Plus Products logo
PLPRF
Plus Products
1.1$0.55flat$0.00N/A0.00Decrease in Short Interest
Gap Up
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00flat$0.00N/A0.00
PCYN
Procyon
0.4$0.60flat$0.00N/A0.00Gap Up
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01flat$0.00N/A0.00Decrease in Short Interest
SANP
Santo Mining
0.5$0.01flat$0.00N/A0.00News Coverage
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$13.23flat$0.00N/A0.00High Trading Volume
Increase in Short Interest
Gap Down
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40flat$0.00N/A0.00
TerrAscend logo
TRSSF
TerrAscend
1.7$10.58flat$0.00N/A0.00Increase in Short Interest
Gap Up
The Flowr logo
FLWPF
The Flowr
1.5$0.25flat$0.00N/A0.00Decrease in Short Interest
Gap Up
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.0$0.31flat$0.00N/A0.00Gap Up
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.